Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2006 1
2008 1
2014 1
2015 1
2016 4
2017 2
2018 4
2019 1
2020 1
2021 2
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Fuzheng Kang-Ai inhibits NSCLC cell proliferation via regulating hsa_circ_0048091/hsa-miR-378g/ARRDC3 pathway.
Tang Q, Wang X, Zhou Q, Li Q, Yang X, Xu M, Wang R, Chen J, Wu W, Wang S. Tang Q, et al. Phytomedicine. 2023 Jun;114:154819. doi: 10.1016/j.phymed.2023.154819. Epub 2023 Apr 11. Phytomedicine. 2023. PMID: 37062135 Free article.
Therefore, more safe and effective drugs are needed. PURPOSE: Fuzheng Kang-Ai (FZKA for short) has been applied as an adjuvant treatment in advanced Non-Small Cell Lung Cancer (NSCLC) patients for decades in China, showing a definitive effect with minimal toxicities …
Therefore, more safe and effective drugs are needed. PURPOSE: Fuzheng Kang-Ai (FZKA for short) has been applied as an adjuvant …
Fuzheng Kang' ai decoction inhibits cell proliferation, migration and invasion by modulating mir-21-5p/human phosphatase and tensin homology deleted on chromosome ten in lung cancer cells.
Jinhua LI, Chunping L, Yueyang Z, Wanyin WU, Pengtao S, Longmei LI, Xiaobing Y, Yushu Z. Jinhua LI, et al. J Tradit Chin Med. 2022 Jun;42(3):344-352. doi: 10.19852/j.cnki.jtcm.2022.03.003. J Tradit Chin Med. 2022. PMID: 35610003 Free PMC article.
OBJECTIVE: To elucidate the potential molecular mechanism by which Fuzheng Kang'ai decoction (, FZKA) inhibits proliferation, migration, and invasion of lung cancer cells. ...
OBJECTIVE: To elucidate the potential molecular mechanism by which Fuzheng Kang'ai decoction (, FZKA) inhibits proliferation, …
Mechanism of Fuzheng Kang'ai Formula Regulating Tumor Microenvironment in Non-Small Cell Lung Cancer.
Tian YL, Fu SB, Li B, Yuan LY, Bing ZT. Tian YL, et al. Chin J Integr Med. 2022 May;28(5):425-433. doi: 10.1007/s11655-021-3451-1. Epub 2021 Sep 21. Chin J Integr Med. 2022. PMID: 34546538
OBJECTIVE: To study the mechanism of Chinese herbal medicine Fuzheng Kang'ai Formula (, FZKA) on tumor microenvironment (TME). ...
OBJECTIVE: To study the mechanism of Chinese herbal medicine Fuzheng Kang'ai Formula (, FZKA) on tumor microenvironment (TME). …
Fuzheng Kang-Ai decoction enhances the effect of Gefitinib-induced cell apoptosis in lung cancer through mitochondrial pathway.
Wang S, Peng Z, Li W, Long S, Xiao S, Wu W. Wang S, et al. Cancer Cell Int. 2020 May 24;20:185. doi: 10.1186/s12935-020-01270-3. eCollection 2020. Cancer Cell Int. 2020. PMID: 32489321 Free PMC article.
BACKGROUND: Our previous clinical study has shown that Chinese herbal medicine (CHM) Fuzheng Kang-Ai (FZKA) decoction is effective in treating advanced lung cancer patients through prolonging the drug resistance to Gefitinib (GFTN). ...Last but not the least, the en …
BACKGROUND: Our previous clinical study has shown that Chinese herbal medicine (CHM) Fuzheng Kang-Ai (FZKA) decoction is effec …
Efficacy and Safety of Fuzheng Yiqi Kang-Ai Decoction Combined with External Irradiation in the Treatment of Undifferentiated Thyroid Carcinoma and Its Influence on Antiangiogenesis.
Bian L, Zhang J, Wang P. Bian L, et al. J Oncol. 2022 May 16;2022:3589924. doi: 10.1155/2022/3589924. eCollection 2022. J Oncol. 2022. PMID: 35615246 Free PMC article.
OBJECTIVE: To explore the efficacy and safety of Fuzheng Yiqi Kang-ai (FZYQKA for short) decoction with external irradiation in the treatment of undifferentiated thyroid carcinoma (UTC) and its influence on antiangiogenesis. ...
OBJECTIVE: To explore the efficacy and safety of Fuzheng Yiqi Kang-ai (FZYQKA for short) decoction with external irradiation i …
GPX4 Plays a Crucial Role in Fuzheng Kang'ai Decoction-Induced Non-Small Cell Lung Cancer Cell Ferroptosis.
Zhao YY, Yang YQ, Sheng HH, Tang Q, Han L, Wang SM, Wu WY. Zhao YY, et al. Front Pharmacol. 2022 Apr 13;13:851680. doi: 10.3389/fphar.2022.851680. eCollection 2022. Front Pharmacol. 2022. PMID: 35496303 Free PMC article.
Background: Fuzheng Kang'ai decoction (FZKA) has been widely used to treat Non-Small Cell Lung Cancer (NSCLC) patients in China for decades, showing definitively curative effects in clinic. ...
Background: Fuzheng Kang'ai decoction (FZKA) has been widely used to treat Non-Small Cell Lung Cancer (NSCLC) patients in Chin …
Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ, He WF, Zhou YS, Liao GY, Li QP, Xiao SJ, Cai JZ. Yang XB, et al. Trials. 2015 Apr 10;16:146. doi: 10.1186/s13063-015-0685-2. Trials. 2015. PMID: 25873045 Free PMC article. Clinical Trial.
The purpose of the present trial is to determine whether CHM (Fuzheng Kang'ai decoction (FZKA), a CHM formula) combined with gefitinib results in longer progression-free survival with less toxicity than gefitinib alone. ...
The purpose of the present trial is to determine whether CHM (Fuzheng Kang'ai decoction (FZKA), a CHM formula) combined with g …
Traditional Chinese medicine, Fuzheng Kang-Ai decoction, inhibits metastasis of lung cancer cells through the STAT3/MMP9 pathway.
Li L, Wang S, Yang X, Long S, Xiao S, Wu W, Hann SS. Li L, et al. Mol Med Rep. 2017 Sep;16(3):2461-2468. doi: 10.3892/mmr.2017.6905. Epub 2017 Jun 30. Mol Med Rep. 2017. PMID: 28677797 Free PMC article.
The present study aimed to uncover the mechanism by which the Chinese herbal medicine, Fuzheng Kang-Ai (FZKA), functions on lung cancer cell metastasis. ...
The present study aimed to uncover the mechanism by which the Chinese herbal medicine, Fuzheng Kang-Ai (FZKA), functions on lu …
Gefitinib plus Fuzheng Kang'ai Formula () in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial.
Yang XB, Chai XS, Wu WY, Long SQ, Deng H, Pan ZQ, He WF, Zhou YS, Liao GY, Xiao SJ. Yang XB, et al. Chin J Integr Med. 2018 Oct;24(10):734-740. doi: 10.1007/s11655-017-2819-8. Epub 2017 Aug 9. Chin J Integr Med. 2018. PMID: 28795387 Clinical Trial.
OBJECTIVE: To evaluate the effect of Fuzheng Kang'ai Formula (, FZKA) plus gefitinib in patients with advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations. ...
OBJECTIVE: To evaluate the effect of Fuzheng Kang'ai Formula (, FZKA) plus gefitinib in patients with advanced non-small cell …
23 results